Literature DB >> 12529670

Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.

C Magnac1, R Porcher, F Davi, J Nataf, B Payelle-Brogard, R P Tang, P Oppezzo, V Lévy, G Dighiero, F Ajchenbaum-Cymbalista.   

Abstract

In B-CLL IgV(H) genes mutational status is a major prognostic factor. Since sequencing of IgV(H) genes is not available in most laboratories, an easily performed surrogate assay is desirable. To identify the best surrogate assay, and to better discriminate prognostic subgroups we analyzed clinical and biological data from 58 typical CLL cases. A higher serum thymidine kinase level (>15 U/l) proved to be a strong predictor of mutational status, and the only independent one among the studied parameters. To further identify prognostic subgroups, cluster analysis was employed on 38 cases on which all data were available, which segregated two groups including 25 and 13 patients, respectively. These two clusters differed by their proliferative potential and appeared to discriminate patients with very different clinical course and outcome. s-TK was strikingly different among these two clusters, suggesting that s-TK level could be used routinely to identify patients at risk of progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12529670     DOI: 10.1038/sj.leu.2402780

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

Review 1.  Prognostic factors in chronic lymphocytic leukemia.

Authors:  Neil E Kay; Tait D Shanafelt
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 3.952

2.  Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer.

Authors:  Yongping Liu; Yang Ling; Qiufeng Qi; Yexin Tang; Jianzhong Xu; Zhou Tong; Guifeng Sheng; Quanliang Yang; Yaodong Pan
Journal:  Exp Ther Med       Date:  2011-08-17       Impact factor: 2.447

3.  Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.

Authors:  Natali Pflug; Jasmin Bahlo; Tait D Shanafelt; Barbara F Eichhorst; Manuela A Bergmann; Thomas Elter; Kathrin Bauer; Gebhart Malchau; Kari G Rabe; Stephan Stilgenbauer; Hartmut Döhner; Ulrich Jäger; Michael J Eckart; Georg Hopfinger; Raymonde Busch; Anna-Maria Fink; Clemens-Martin Wendtner; Kirsten Fischer; Neil E Kay; Michael Hallek
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

Review 4.  Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Authors:  Paula Cramer; Michael Hallek
Journal:  Nat Rev Clin Oncol       Date:  2010-10-19       Impact factor: 66.675

5.  Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.

Authors:  Wei Xu; Xin Cao; Kou-Rong Miao; Chun Qiao; Yu-Jie Wu; Qiong Liu; Lei Fan; Jian-Yong Li
Journal:  Int J Hematol       Date:  2009-07-24       Impact factor: 2.490

6.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

7.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

Review 8.  The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.

Authors:  Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas
Journal:  Diagnostics (Basel)       Date:  2021-05-10

9.  Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Authors:  Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 10.  Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.

Authors:  Xiaoya Yun; Ya Zhang; Xin Wang
Journal:  Biomark Res       Date:  2020-09-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.